SARS-CoV-2 PLpro結合薬候補の親和性を一般化アンサンブル法を用いて評価
Masashi Muramoto1, Simon Hikiri2, Suzuka Saito1
1Graduate School of Life Sciences, Ritsumeikan University, 1-1-1 Noji-higashi, Kusatsu, Shiga, 525-8577, Japan.
Scientific reports
|January 11, 2026
まとめ
我々は、タンパク質結合を阻害する化合物をスクリーニングするための新しい計算方法である多次元仮想システム連動分子動力学(mD-VcMD)を開発した。この方法は、SARS-CoV-2パパイン様プロテアーゼ(PLpro)に対する化合物の有効性を正確に予測する。
科学分野:
- 計算化学
- 分子動力学
- 創薬
背景:
- リガンドと受容体の結合は、生物学的プロセスと創薬において重要です。
- 効果的な阻害薬を特定するには、正確なスクリーニング方法が必要です。
研究 の 目的:
- リガンドと受容体の結合を阻害する化合物をスクリーニングするための新規計算手順を確立および検証する。
- SARS-CoV-2パパイン様プロテアーゼ(PLpro)の阻害薬を特定する上で、この方法の有効性を評価する。
主な方法:
- 一般化アンサンブル法である多次元仮想システム連動分子動力学(mD-VcMD)を採用しました。
- 自由エネルギーランドスケープを生成するために、柔軟な受容体と化合物を明示的な溶媒中でシミュレートしました。
- 4つのSARS-CoV-2 PLpro阻害薬の自由エネルギー盆地と結合モードを分析しました。
主要な成果:
- 試験されたすべての化合物に対して、mD-VcMD法は漏斗状の自由エネルギーランドスケープを生成しました。
- 自由エネルギー盆地の確率は、測定された解離定数とよく相関しました。
- 構造クラスタリングにより、酵素阻害活性と相関する結合モードが明らかになりました。
結論:
- 提案されたmD-VcMD手順は、化合物のスクリーニングと潜在的な阻害薬の選択に効果的です。
- この方法は、SARS-CoV-2 PLproのようなウイルスプロテアーゼを標的とする薬候補を特定するための信頼できるアプローチを提供します。
関連する概念動画
Structure-Activity Relationships and Drug Design
1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
Protein-Drug Binding: Determination Methods
610
Determining protein-drug binding can be achieved through indirect and direct methods, each providing valuable insights into the interaction between proteins and drugs.
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...
610
Ligand Binding Sites
14.9K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
14.9K
Protein-Drug Binding: Mechanism and Kinetics
1.6K
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
1.6K
The Equilibrium Binding Constant and Binding Strength
14.8K
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
14.8K
Drug-Receptor Interactions
7.3K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
7.3K


